Friday, February 01, 2013 12:11:15 PM
Gerald
_______________________________
I asked Gerald if there was any retesting pending at this time.
Hello Jeff,
I stated in my last Chairman's Blog post that we were moving forward with IND-enabling and human clinical studies (This is huge news) , and that further testing would be done in academia to determine optimal rodent model dosing regimens, which have nothing to do with human dosing regimens.
Why would the Company need to do a retest, and where did this notion come from? It certainly did not come from me. The results are the results. We believe them as they are and there is clear efficacy.
Gerald
http://www.thechairmansblog.com/author/gerald-commissiong
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM